Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models.

We recently demonstrated that p38α is required to maintain colorectal cancer (CRC) metabolism, as its inhibition leads to FoxO3A activation, autophagy, cell death, and tumor growth reduction both in vitro and in vivo. Here we show that inhibition of p38α is followed by TRAIL-mediated activation of caspase-8 and FoxO3A-dependent HER3 upregulation with consequent overactivation of the MEK-ERK1/2 survival pathway. p38α and MEK combined inhibition specifically induces apoptosis by enabling TRAIL signaling propagation through t-Bid and caspase-3, and fosters cell death in CRC cells and preclinical mouse models. Current MEK1-directed pharmacological strategies could thus be exploited, in combination with p38α inhibition, to develop new approaches for CRC treatment.

[1]  Gabriella De Vita,et al.  p38α MAP Kinase as a Sensor of Reactive Oxygen Species in Tumorigenesis , 2007 .

[2]  Wafik S El-Deiry,et al.  TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.

[3]  A. Cuadrado,et al.  p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. , 2007, Cancer cell.

[4]  Yi-Hsien Hsieh,et al.  p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. , 2007, Cancer research.

[5]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[6]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jukka Westermarck,et al.  Phosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  S. Cook,et al.  Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM , 2008, Oncogene.

[9]  J. Lyons,et al.  Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. , 2005, Current opinion in pharmacology.

[10]  P. Bragado,et al.  Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. , 2009, Cancer research.

[11]  A. Causse,et al.  Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. , 2011, Cancer research.

[12]  A. Seifalian,et al.  Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment. , 2011, International journal of oncology.

[13]  Sarat Chandarlapaty,et al.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.

[14]  L. Platanias,et al.  Mitochondrial Reactive Oxygen Species Activation of p38 Mitogen-Activated Protein Kinase Is Required for Hypoxia Signaling , 2005, Molecular and Cellular Biology.

[15]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[16]  A. Cuadrado,et al.  Mechanisms and functions of p38 MAPK signalling. , 2010, The Biochemical journal.

[17]  C. Arteaga,et al.  p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. , 2002, Journal of Cell Science.

[18]  C. Arteaga,et al.  p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. , 2002, Journal of cell science.

[19]  Y. Hsieh,et al.  p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. , 2007, Cancer research.

[20]  K. Kinzler,et al.  Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.

[21]  M. Barbacid,et al.  p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation , 2007, Nature Genetics.

[22]  Á. Avivar-Valderas,et al.  p38α Signaling Induces Anoikis and Lumen Formation During Mammary Morphogenesis , 2011, Science Signaling.

[23]  Christian Haslinger,et al.  p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway , 2007, Nature Genetics.

[24]  G. Ingravallo,et al.  p38α blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1α- to FoxO-dependent transcription , 2009, Cell Death and Differentiation.

[25]  B. Nico,et al.  A novel cell type-specific role of p38α in the control of autophagy and cell death in colorectal cancer cells , 2007, Cell Death and Differentiation.

[26]  Steven P. Gygi,et al.  Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase , 2004, Science.

[27]  Eun-Jung Lee,et al.  p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. , 2003, Cancer research.

[28]  F. Beier,et al.  p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation , 2004, Oncogene.

[29]  C. Simone,et al.  Inhibition of p38α unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism , 2009, Autophagy.

[30]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[31]  C. Simone,et al.  The AMPK-FoxO3A axis as a target for cancer treatment , 2010, Cell cycle.

[32]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[33]  S. Pattingre,et al.  Amino Acids Interfere with the ERK1/2-dependent Control of Macroautophagy by Controlling the Activation of Raf-1 in Human Colon Cancer HT-29 Cells* , 2003, The Journal of Biological Chemistry.

[34]  S. Varadarajan,et al.  TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1 , 2010, Cell Death and Differentiation.

[35]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[36]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[37]  J. Martinou,et al.  Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. , 2001, Molecular cell.

[38]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[39]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[40]  L. Saltz,et al.  Evolving treatment of advanced colon cancer. , 2009, Annual review of medicine.

[41]  Jing-Yuan Fang,et al.  The MAPK signalling pathways and colorectal cancer. , 2005, The Lancet. Oncology.

[42]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[43]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[44]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[45]  Matthew R. Lee,et al.  MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein , 2005 .

[46]  J. Westermarck,et al.  p38α and p38δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells , 2007, Oncogene.

[47]  S. Cook,et al.  Tumour cell survival signalling by the ERK1/2 pathway , 2009, Cell Death and Differentiation.

[48]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[49]  Matthew R. Lee,et al.  MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. , 2005, Current medicinal chemistry.

[50]  S. Morini,et al.  The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies , 2011, Journal of carcinogenesis.

[51]  A. Rustgi,et al.  The genetics of hereditary colon cancer. , 2007, Genes & development.

[52]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[53]  C. Simone,et al.  Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors. , 2008, Cancer letters.